1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
LadRx Corporation

LadRx Corporation

LADX
LadRx CorporationUS flagOther OTC
0.00
USD
- -
- -
99.00Market Cap
LadRx Corporation
LADX
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
TTM
FRC
399.11
3.84
8.36
2.61
5.47
1.1
0.99
1.48
0.42
0.81
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-201.66
15.67
-482.54
-469.17
-866.24
-332.36
-581.19
-375.79
-145.52
-41.08
-21.53
-19.34
-35.52
-10.57
0.68
-3.21
-5.04
Basic EPS, GAAP
-517.13
-570.06
-559.47
-501.09
-434.03
-458.1
-475.31
-376.53
-113.28
-35.15
-17.27
-17.79
-32.77
-10.73
2.08
-2.65
-3.75
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.46
1.25
0.14
- -
- -
Dividend per Share
1,086.95
1,168.86
683.41
591.34
151.88
731.25
397.82
130.75
64.72
60.53
45.2
24.32
1.94
-2.93
0.22
-2.87
-4.31
Book Value per Share
1,079.9
1,161.83
678.23
587.73
149.26
729.27
396.17
129.76
64.06
60.53
45.2
24.32
1.94
-2.93
0.22
-2.87
-4.31
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
10
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
-80.47
-16,750.6
-9,061.53
-21,051.73
-9,198.29
-49,605.63
-63,278.22
-26,128.92
-28,356.71
-3,299.31
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-5
- -
-14
-18
-47
-30
-59
-51
-35
-13
-7
-7
-13
-4
- -
-2
-2
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-50.53
408.46
-5,769.82
-17,963.87
-15,828.48
-30,117.98
-58,587.19
-25,385.61
-34,986.43
-5,085.44
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
28
30
24
30
10
65
41
41
17
20
15
9
5
- -
- -
-1
-2
Working Capital
- -
- -
- -
- -
- -
- -
- -
18
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
28
31
24
30
11
68
44
25
18
20
15
9
5
- -
- -
-1
-2
Total Equity
- -
-56.86
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-1,929.57
- -
- -
Return on Invested Capital (%)
- -
1.39
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
202.1
- -
248.69
Return on Capital (%)
-21.8
1.39
-52.62
-66.02
-232.62
-76.66
-104.63
-148.59
-165.01
-66.03
-40.28
-55.66
-277.38
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'24
Dec'24
Mar'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
- -
- -
Market Capitalization
1
1
1

Working Capital

FRC

•

in mil. unless spec.
Sep'24
Dec'24
Mar'25
Total Current Assets
- -
1
- -
Cash, Cash Equivalents & STI
- -
1
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
2
2
2
Payables & Accruals
2
2
2
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-141.08%
-258.41%
-1,422.19%
Free Cash Flow
-43.6%
-60.77%
-229.24%
Net Income, GAAP
-64.17%
-116.89%
-496.98%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
-2.48
6.45
-1.65
- -
0.68
2024
0.38
-2.59
-1.67
- -
-3.21
2025
-1.45
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
0.15
- -
- -
- -
0.14
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Anterogen.Co.,Ltd. (065660.KQ)
Roquefort Therapeutics plc (ROQ.L)
CytoDyn Inc. (CYDY)
CalciMedica, Inc. (CALC)
Genovate Biotechnology Co., Ltd. (4130.TWO)
Vericel Corporation (VCEL)
Business
LadRx Corporation (NASDAQ: LADX) develops and commercializes innovative oncology therapeutics and companion diagnostics targeting difficult-to-treat cancers. The company offers a pipeline of targeted drug candidates, including aldoxorubicin, a conjugated form of the anthracycline doxorubicin designed for improved efficacy and reduced cardiotoxicity in solid tumors such as soft tissue sarcomas, small cell lung cancer, and glioblastoma; and other antibody-drug conjugates and linker technologies for precision oncology applications. Its services encompass clinical-stage development programs, proprietary linker technology platforms for site-specific drug conjugation, and companion diagnostic assays to identify responsive patient populations; the company previously marketed products under brands like Biorubicin in select international markets. LadRx Corporation operates primarily in the United States and Europe, with clinical trials conducted globally, and maintains research collaborations with academic institutions and biotech partners. Founded in 1985 as Cytrx Corporation and headquartered in Los Angeles, California, the company underwent a significant rebranding to LadRx Corporation in 2024 to better reflect its focus on leadership in antibody-drug conjugate (ADC) technologies for cancer treatment; this name change coincided with strategic shifts including pipeline prioritization on ADC programs, divestiture of non-core assets, and enhanced partnerships for manufacturing scale-up announced in late 2024. In 2025, LadRx expanded its oncology portfolio through a key licensing agreement for a novel ADC payload technology and initiated Phase 2 trials for aldoxorubicin combinations in metastatic breast cancer, marking major advancements in its clinical development efforts.

Company News

Company News APIChatGPT

  • globenewswire.com

    LadRx Corporation, Inc. to Present at the Virtual Life Science Investor Forum March 13th

  • businesswire.com

    LadRx Planning NDA Submission under 505(b)(2) for Aldoxorubicin and Other Updates